Bristol-myers Squibb Compnay

Flexus Biosciences, Inc.

Syngene International Limited

Dupont Pharmaceuticals Company

Innate Tumor Immunity, Inc.

Jay A Markwalder

Steven P Seitz

James Aaron Balog

David K Williams

Audris Huang

Weifang Shan

Emily Charlotte Cherney

Susheel Jethanand Nara

Saumya Roy

Jay Patrick Powers

Juan Carlos Jaen

Hunter Paul Shunatona

Maksim Osipov

Maureen Kay Reilly

Mikhail Zibinsky

Hilary Plake Beck

James Ross Walker

Srinivas Cheruku

Weiwei Guo

Ramesh Kumar Sistla

Soodamani Thangavel

Nagalakshmi Pulicharla

Ashvinikumar V Gavai

Srinivasan Thangathirupathy

Yadagiri Kanyaboina

Natesan Murugesan

Amy C Hart

Liping Zhang

Libing Chen

Sunil Kumar Mandal

Susan R Sherk

Jeffrey A Robl

Chunhong He

Shomir Ghosh

Soong-Hoon Kim

Brian E Fink

Yan Shi

Scott Hunter Watterson

William R Roush

Derek J Norris

Yong Zhang

Prasanna Sivaprakasam

Philip D Stein

Liqi He

Christine M Tarby

Ashok Vinayak Purandare

Daniel O'Malley

David J Carini

Hua Gong

Shefali Srivastava

Andrew Forrest Donnell

Jennifer Inghrim

Bin Chen

Jennifer Donnell

The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

NLRP3 modulators

The present invention provides compounds of formula (I) wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.

Inhibitors of indoleamine 2,3-dioxygenase and methods of their use

The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.

The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

IDO inhibitors

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

Immunoregulatory agents

There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention. 

Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer

There are disclosed compounds of Formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. 

There are disclosed compounds that are inhibitors of EZH2, pharmaceutical compositions containing said compounds and methods of treating hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases utilizing the compounds of the invention.

Inhibitors of lysine methyl transferase

There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention. 

Growing community of inventors

Lahaska, PA, United States of America

Jay A Markwalder